The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | DREAMM-6: Belamaf with BorDex for R/R myeloma
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, shares the preliminary results of the Phase I DREAMM-6 trial (NCT03544281) evaluating the safety and efficacy of belantamab mefodotin (belamaf) in combination with bortezomib and dexamethasone (BorDex) in patients with relapsed/refractory (R/R) multiple myeloma. The interim data shows the combination is well tolerated with no new safety signals or dose-limiting toxicities. Patients have displayed a significant overall response rate of 78%, supporting the continued investigation of the combination in Phase III trials. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Honoraria: Takeda, Abbvie, GSK
Consultancy: BMS, Janssen, GSK
